Neuroprotection with a brain-penetrating biologic tumor necrosis factor inhibitor

Journal of Pharmacology and Experimental Therapeutics

Volumn 339, Issue 2, 2011, Pages 618-623

  Zhou, Qing Hui ^a   Sumbria, Rachita ^a   Hui, Eric Ka Wai ^b   Lu, Jeff Zhiqiang ^b   Boado, Ruben J ^a   Pardridge, William M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ArmaGen Technologies Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; APOMORPHINE; CHIMERIC MONOCLONAL ANTIBODY AGAINST MOUSE TRANSFERRIN RECEPTOR TUMOR NECROSIS FACTOR RECEPTOR FUSION PROTEIN; ETANERCEPT; HYBRID PROTEIN; OXIDOPAMINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BEHAVIOR; BLOOD BRAIN BARRIER; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FORELIMB; IMMUNE RESPONSE; IN VIVO STUDY; MOUSE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; ROTATION; STRIATE CORTEX; TREATMENT DURATION; VIBRISSA;

ANIMALS; ANTIBODIES, MONOCLONAL; BEHAVIOR, ANIMAL; BLOOD-BRAIN BARRIER; BRAIN; CHO CELLS; CONTROL GROUPS; CORPUS STRIATUM; CRICETINAE; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, INBRED C57BL; NEUROPROTECTIVE AGENTS; PARKINSONIAN DISORDERS; RATS; RECEPTORS, TRANSFERRIN; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; SUBSTANTIA NIGRA; TUMOR NECROSIS FACTOR DECOY RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA; TYROSINE 3-MONOOXYGENASE;

EID: 80054788511     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.185876     Document Type: Article

References (29)

1. Boado RJ, Hui EK, Lu JZ, and Pardridge WM (2010) Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular Trojan horse. J Pharmacol Exp Ther 333:961-969.
2. Boado RJ, Zhang Y, Wang Y, and Pardridge WM (2009) Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse. Biotechnol Bioeng 102:1251-1258.
3. Boado RJ, Zhang Y, Zhang Y, and Pardridge WM (2007) Humanization of antihuman insulin receptor antibody for drug targeting across the human blood-brain barrier. Biotechnol Bioeng 96:381-391. (Pubitemid 46232272)
4. Chen G and Goeddel DV (2002) TNF-R1 signaling: a beautiful pathway. Science 296:1634-1635. (Pubitemid 34579145)
5. De Groot AS, Moise L, McMurry JA, Wambre E, Van Overtvelt L, Moingeon P, Scott DW, and Martin W (2008) Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes." Blood 112:3303-3311.
6. Dickson P, Peinovich M, McEntee M, Lester T, Le S, Krieger A, Manuel H, Jabagat C, Passage M, and Kakkis ED (2008) Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I. J Clin Invest 118:2868-2876.
7. Ferger B, Leng A, Mura A, Hengerer B, and Feldon J (2004) Genetic ablation of tumor necrosis factor-α (TNF-α) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum. J Neurochem 89:822-833. (Pubitemid 38684730)
8. Fu A, Zhou QH, Hui EK, Lu JZ, Boado RJ, and Pardridge WM (2010) Intravenous treatment of experimental Parkinson's disease in the mouse with an IgG-GDNF fusion protein that penetrates the blood-brain barrier. Brain Res 1352:208-213.
9. He P, Zhong Z, Lindholm K, Berning L, Lee W, Lemere C, Staufenbiel M, Li R, and Shen Y (2007) Deletion of tumor necrosis factor death receptor inhibits amyloid beta generation and prevents learning and memory deficits in Alzheimer's mice. J Cell Biol 178:829-841. (Pubitemid 47347367)
10. Himmerich H, Fulda S, Linseisen J, Seiler H, Wolfram G, Himmerich S, Gedrich K, Kloiber S, Lucae S, Ising M, et al. (2008) Depression, comorbidities and the TNF-αsystem. Eur Psychiatry 23:421-429.
11. Hui EK, Boado RJ, and Pardridge WM (2009) Tumor necrosis factor receptor-IgG fusion protein for targeted-drug delivery across the human blood-brain barrier. Mol Pharm 6:1536-1543.
12. Kanda Y, Yamane-Ohnuki N, Sakai N, Yamano K, Nakano R, Inoue M, Misaka H, Iida S, Wakitani M, Konno Y, et al. (2006) Comparison of cell lines for stable production of fucose-negative antibodies with enhanced ADCC. Biotechnol Bioeng 94:680-688. (Pubitemid 44014199)
13. Lee HJ, Engelhardt B, Lesley J, Bickel U, and Pardridge WM (2000) Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse. J Pharmacol Exp Ther 292:1048-1052. (Pubitemid 30136600)
14. Machado A, Herrera AJ, Venero JL, Santiago M, De Pablos RM, Villarán RF, Espinosa-Oliva AM, Argüelles S, Sarmiento M, Delgado-Cortés MJ, et al. (2011) Peripheral inflammation increases the damage in animal models of nigrostriatal dopaminergic neurodegeneration: possible implication in Parkinson's disease incidence. Parkinsons Dis 2011:393769.
15. Marchand F, Tsantoulas C, Singh D, Grist J, Clark AK, Bradbury EJ, and McMahon SB (2009) Effects of Etanercept and Minocycline in a rat model of spinal cord injury. Eur J Pain 13:673-681.
16. McCoy MK, Martinez TN, Ruhn KA, Szymkowski DE, Smith CG, Botterman BR, Tansey KE, and Tansey MG (2006) Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. J Neurosci 26:9365-9375. (Pubitemid 44396849)
17. Morita C, Horiuchi T, Tsukamoto H, Hatta N, Kikuchi Y, Arinobu Y, Otsuka T, Sawabe T, Harashima S, Nagasawa K, et al. (2001) Association of tumor necrosis factor receptor type II polymorphism 196R with systemic lupus erythematosus in the Japanese: molecular and functional analysis. Arthritis Rheum 44:2819-2827. (Pubitemid 34016201)
18. Pardridge WM (2010) Biopharmaceutical drug targeting to the brain. J Drug Target 18:157-167.
19. Pardridge WM, Kang YS, Buciak JL, and Yang J (1995) Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. Pharm Res 12:807-816.
20. Peppel K, Crawford D, and Beutler B (1991) A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med 174:1483-1489.
21. Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, and Wagner C (2002) Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301:418-426. (Pubitemid 34429950)
22. Scallon BJ, Trinh H, Nedelman M, Brennan FM, Feldmann M, and Ghrayeb J (1995) Functional comparisons of different tumour necrosis factor receptor/IgG fusion proteins. Cytokine 7:759-770.
23. Shohami E, Novikov M, Bass R, Yamin A, and Gallily R (1994) Closed head injury triggers early production of TNF α and IL-6 by brain tissue. J Cereb Blood Flow Metab 14:615-619. (Pubitemid 24198404)
24. Shoji-Hosaka E, Kobayashi Y, Wakitani M, Uchida K, Niwa R, Nakamura K, and Shitara K (2006) Enhanced Fc-dependent cellular cytotoxicity of Fc fusion proteins derived from TNF receptor II and LFA-3 by fucose removal from Asn-linked oligosaccharides. J Biochem 140:777-783. (Pubitemid 46941006)
25. Sriram K, Matheson JM, Benkovic SA, Miller DB, Luster MI, and O'Callaghan JP (2002) Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. FASEB J 16:1474-1476.
26. Tansey MG and Szymkowski DE (2009) The TNF superfamily in 2009: new pathways, new indications, and new drugs. Drug Discov Today 14:1082-1088.
27. Zhao C, Ling Z, Newman MB, Bhatia A, and Carvey PM (2007) TNF-α knockout and minocycline treatment attenuates blood-brain barrier leakage in MPTP-treated mice. Neurobiol Dis 26:36-46. (Pubitemid 46437443)
28. Zhou QH, Boado RJ, Hui EK, Lu JZ, and Pardridge WM (2011a) Brain-penetrating tumor necrosis factor decoy receptor in the mouse. Drug Metab Dispos 39:71-76.
29. Zhou QH, Boado RJ, Hui EK, Lu JZ, and Pardridge WM (2011b) Chronic dosing of mice with a transferrin receptor monoclonal antibody-glial-derived neurotrophic factor fusion protein. Drug Metab Dispos 39:1149-1154.